Sugi Predict

Sugi Predict / Compounds / SCHEMBL15344922

SCHEMBL15344922

SCHEMBL15344922

Cn1ccc2ccncc2c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD9 Q9H8M2 3/20 0.44
▸ MAPT P10636 1/20 0.42
▸ HTR2A P28223 4/20 0.41
▸ HTR2C P28335 1/20 0.41
▸ HTR2B P41595 1/20 0.41
▸ BRD4 O60885 5/20 0.41
▸ TAF1 P21675 2/20 0.41
▸ BRPF1 P55201 2/20 0.41
▸ CREBBP Q92793 2/20 0.41
▸ CECR2 Q9BXF3 2/20 0.41
▸ HTR1A P08908 3/20 0.39
▸ DRD2 P14416 2/20 0.39
▸ KDM4C Q9H3R0 1/20 0.39
▸ STING1 Q86WV6 1/20 0.38
▸ HASPIN Q8TF76 1/20 0.37
▸ FEN1 P39748 1/20 0.37
▸ GRM2 Q14416 1/20 0.36
▸ TNF P01375 1/20 0.36
▸ TGFBR1 P36897 1/20 0.36
▸ ACVR1 Q04771 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29720794 1.00 BRD9 (0.44) BRD9MAPTHTR2AHTR2CHTR2B
Hydrochloric Acid SCHEMBL29721035 0.98 BRD9 (0.43) BRD9MAPTHTR2AHTR2CHTR2B
Trifluoroacetic Acid SCHEMBL29721133 0.87 STING1 (0.39) BRD9MAPTHTR2AHTR2CHTR2B
SCHEMBL4772542 0.85 BRD9 (0.44) BRD9MAPTHTR2AHTR2CHTR2B
SCHEMBL30441185 0.84 BRD9 (0.38) BRD9BRD4TAF1BRPF1CREBBP
SCHEMBL28001902 0.78 STING1 (0.38) MAPTHTR2AHTR2CHTR2BHTR1A
SCHEMBL23425580 0.77 HTR2A (0.48) HTR2AHTR2CHTR2BHTR1ADRD2
SCHEMBL15341744 0.77 HTR2A (0.44) HTR2AHTR2CHTR2BHTR1ADRD2
SCHEMBL28948256 0.77 HTR2A (0.38) MAPTHTR2AHTR2CHTR2BHTR1A
SCHEMBL30171226 0.77 HTR2A (0.38) MAPTHTR2AHTR2CHTR2BHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4134364-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2025-07-30 — — EP disclosed
US-12351579-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-07-08 — — US disclosed
US-20240182490-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2024-06-06 — — US disclosed
US-11884680-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2024-01-30 — — US disclosed
CN-116322780-A Compounds and uses thereof 福宏治疗公司 2023-06-23 — — CN disclosed
US-20230142883-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 — — US disclosed
CN-115894479-A Polycyclic derivative, composition and pharmaceutical application thereof 海思科医药集团股份有限公司 2023-04-04 — — CN disclosed
EP-4134364-A2 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2023-02-15 — — EP disclosed
EP-4134364-A2 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2023-02-15 — — EP disclosed
US-20220315601-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2022-10-06 — — US disclosed
US-20150183784-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-07-02 — — US disclosed
US-9034900-B2 Bromodomain inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-05-19 — — US disclosed
US-9034900-B2 Bromodomain inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-05-19 — — US disclosed
US-9034900-B2 Bromodomain inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-05-19 — — US disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed
WO-2015058160-A1 BROMODOMAIN INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2015-04-23 — — WO disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 — — US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182490-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 BRD9 19/4885MAPT 2462/4885HTR2A 4372/4885
US-20220315601-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 BRD9 19/4885MAPT 2462/4885HTR2A 4372/4885
US-20230142883-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 BRD9 290/4885MAPT 1498/4885HTR2A 4196/4885
US-20150111885-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 BRD9 19/4885MAPT 2462/4885HTR2A 4372/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 BRD9 3522/4885MAPT 1627/4885HTR2A 3913/4885
US-20150183784-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 BRD9 19/4885MAPT 2462/4885HTR2A 4372/4885
US-12351579-B2 Compounds and uses thereof VHL, TFEB, BECN1 BRD9 290/4885MAPT 1498/4885HTR2A 4196/4885
US-11884680-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 BRD9 19/4885MAPT 2462/4885HTR2A 4372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.